Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) EPS (Basic) (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EPS (Basic) for 8 consecutive years, with -$0.38 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 152.78% to -$0.38 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.62 through Dec 2025, down 803.45% year-over-year, with the annual reading at -$1.79 for FY2025, 55.91% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.38 at Outlook Therapeutics, down from -$0.19 in the prior quarter.
  • The five-year high for EPS (Basic) was $0.72 in Q4 2024, with the low at -$1.5 in Q1 2025.